Omeros Corporation (OMER)

The immediate catalyst here is undeniable: the stock has rallied nearly 70% in two weeks, driven by a Novo Nordisk deal windfall and optimism over a new drug launch. This momentum is the primary driver for the short-term bullish stance; the price action is decoupling from the historical downtrend, and the options market is screaming for further upside with heavy bets on a 2x+ move. However, the long-term picture remains murky. Despite the recent surge, the business has suffered a catastrophic 60% decline over the last nine years, with four consecutive years of negative annual returns prior to this recovery. The fundamentals are fragile: negative book value, negative operating cash flow, and a forward P/E that implies significant future growth expectations which are hard to verify given the history. The recent rally feels more like a speculative event-driven spike than a fundamental re-rating of the company's core health. While the short-term trend is clearly upward due to the news catalyst, the lack of a sustainable dividend and the precarious balance sheet prevent a confident long-term buy recommendation at these elevated levels.